TY - JOUR
T1 - Molecular Aspects concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
AU - Valdes-Balbin, Yury
AU - Santana-Mederos, Darielys
AU - Paquet, Françoise
AU - Fernandez, Sonsire
AU - Climent, Yanet
AU - Chiodo, Fabrizio
AU - Rodríguez, Laura
AU - Sanchez Ramirez, Belinda
AU - Leon, Kalet
AU - Hernandez, Tays
AU - Castellanos-Serra, Lila
AU - Garrido, Raine
AU - Chen, Guang Wu
AU - Garcia-Rivera, Dagmar
AU - Rivera, Daniel G.
AU - Verez-Bencomo, Vicente
N1 - Funding Information: We are grateful to Fondo de Ciencia e Innovaci? n (FONCI, Cuba) for financial support (Project-2020-20). We thank Gail Reed for editing English grammar. Funding Information: We are grateful to Fondo de Ciencia e Innovación (FONCI, Cuba) for financial support (Project-2020-20). We thank Gail Reed for editing English grammar. Publisher Copyright: © 2021 The Authors. Published by American Chemical Society. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/5/26
Y1 - 2021/5/26
N2 - The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.
AB - The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.
UR - http://www.scopus.com/inward/record.url?scp=85105033783&partnerID=8YFLogxK
U2 - https://doi.org/10.1021/acscentsci.1c00216
DO - https://doi.org/10.1021/acscentsci.1c00216
M3 - Article
C2 - 34075345
SN - 2374-7943
VL - 7
SP - 757
EP - 767
JO - ACS central science
JF - ACS central science
IS - 5
ER -